More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in ...

Company Overview - Accuray Incorporated has introduced the CyberKnife® System at the CyberKnife Center Salzburg, marking the first use of this technology in Austria, which enhances access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT) [1][4] - The CyberKnife S7™ System allows for ultra-hypofractionated radiation therapy, delivering high doses of targeted radiation in just one to five outpatient sessions, significantly reducing the treatment time compared to conventional methods that often require 30-40 sessions [2][3] Clinical Impact - Evidence suggests that ultra-hypofractionation provides clinical outcomes comparable to conventional fractionation while reducing the number of treatments and overall care costs, leading to increased adoption of such treatments as standard care [3] - The CyberKnife System is viewed as a significant advancement in cancer care, enabling patients to receive precise and effective treatment in a shorter timeframe, which positively impacts their quality of life [5] Market Context - Cancer cases in Austria are projected to increase by nearly 25% from 2022 to 2040, highlighting the growing need for advanced cancer treatment options [4] - Despite Austria's strong reimbursement for oncology medications, the availability of radiotherapy equipment is 27% lower than the EU average, indicating a need for continued investment in technologies like the CyberKnife System to address this gap [4]